Premium
Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase
Author(s) -
Kukreja R C
Publication year - 2007
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1038/sj.bjp.0707132
Subject(s) - sildenafil , medicine , tadalafil , vardenafil , erectile dysfunction , pharmacology , pulmonary hypertension , cardiology , heart failure , angina , nitric oxide , cardioprotection , ischemia , myocardial infarction
During the past 18 years, sildenafil has evolved from a potential anti‐angina drug to an on‐demand treatment for erectile dysfunction and more recently to a new orally active treatment for pulmonary hypertension. Recent studies suggest that the drug has powerful cardioprotective effect against ischemia/reperfusion injury, doxorubicin‐induced cardiomyopathy and anti‐hypertensive effect induced by chronic inhibition of nitric oxide synthase in animals. Based on several recent basic and clinical studies, it is clear that sildenafil and other clinically approved type‐5 phosphodiesterase‐5 inhibitors including vardenafil and tadalafil will eventually be developed for several cardiovascular indications including essential hypertension, endothelial dysfunction, ischemia/reperfusion injury, myocardial infarction, ventricular remodeling and heart failure. British Journal of Pharmacology (2007) 150 , 538–540. doi: 10.1038/sj.bjp.0707132